Series D+
$3.7m
With the Omicron variant hits the world, Pictor runs its clinical trials in the US, New Zealand, Germany, and India and successfully raises $3,8M
Diagnostics company Pictor is running COVID antibody assay trials across four countries and has raised $3,748,921 of a targeted $7 million Series F, with the shortfall to be offered at a higher share price.